Daiichi Sankyo (United Kingdom)

Recent papers from Daiichi Sankyo (United Kingdom)

1. Early Direct Oral Anticoagulant Initiation After Intracranial Hemorrhage Among Japanese Patients With Nonvalvular Atrial Fibrillation ― SAFE-ICH Registry 12-Month Outcomes ―Circulation Reports · 2026
2. Development of Potent and Orally Bioavailable MALT1 Inhibitors for Sjogren’s Syndrome: Efficacy and Safety AssessmentACS Medicinal Chemistry Letters · 2026
3. Influence of pH, Alcohol Structure, and Temperature on Lenalidomide Alcoholysis with Implications for Pharmaceutical Quality ControlChemical and Pharmaceutical Bulletin · 2026
4. Discovery of Forvisirvat (DS-7830a/SP-624), a Brain-Penetrant Sirtuin 6 Activator Derived from Griseofulvin with Antidepressant-Like EffectsACS Medicinal Chemistry Letters · 2026
5. Implementation of a National Pediatric Cancer Registry in Ethiopia: A systems (“A3”) thinking approachPLoS ONE · 2026
6. Absolute ¹⁹F-qNMR Quantification of Fluorinated Pharmaceuticals: Fluorometholone, Flurbiprofen, and FlutamideChemical and Pharmaceutical Bulletin · 2026
7. Pharmacological properties and clinical trial results of datopotamab deruxtecan (Dato-DXd, Datroway®)Folia Pharmacologica Japonica · 2026
8. Assessing the effectiveness of the TURALIO (pexidartinib) risk evaluation and mitigation strategy program: patient knowledge, attitudes, and behavior survey (2020–2024)Patient Related Outcome Measures · 2026
9. Real-world Treatment Patterns Among Patients With Chemotherapy-induced Peripheral Neuropathy in China: The Retrospective, Observational ReTARdant Study (P8-14.008)Neurology · 2026
10. Peripheral T-cell Lymphoma in Japan: Real-World Patient Characteristics, Treatment Patterns, Healthcare Resource Utilization, and CostsJournal of health economics and outcomes research · 2026
11. EZH1/2 inhibition improves immunotherapy response through MHC Class II de-repression and neutrophil reprogramming2026
12. REJOICE-Ovarian01: Phase 3 part of a phase 2/3 study evaluating raludotatug deruxtecan (R-DXd) versus treatment of physician’s choice in patients with platinum-resistant ovarian cancer.Journal of Clinical Oncology · 2026
13. Integrated spatial transcriptomics, single-nucleus RNA sequencing, and histopathology to reveal immune-suppressive niches in colorectal cancer liver metastases.Journal of Clinical Oncology · 2026
14. Additional health-related quality of life (HRQoL) analysis from DESTINY-Gastric04 (DG-04), a randomized phase 3 study of trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) unresectable/metastatic gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA).Journal of Clinical Oncology · 2026
15. Exposure–response (E–R) analyses of efficacy and safety with raludotatug deruxtecan (R-DXd), a CDH6-directed antibod-drug conjugate (ADC), to inform dose selection for phase (Ph) 3 development in platinum-resistant ovarian cancer (PROC).Journal of Clinical Oncology · 2026
16. Edoxaban for Stroke Prevention in Atrial Fibrillation in Spain and Portugal: 4-Year Follow-Up of the Observational ETNA-AF-Europe StudyJournal of Clinical Medicine · 2026
17. Estimating the societal impact of medical interventions: a case study in metastatic breast cancerJournal of Comparative Effectiveness Research · 2026
18. Effectiveness and Safety of Bempedoic Acid in Taiwanese Patients With Hypercholesterolemia: A Pragmatic Phase 4 Study (CLEAR Taiwan Study)Journal of the American Heart Association · 2026
19. Association of Edoxaban Pharmacokinetics With Bleeding in Older Patients With Atrial Fibrillation Treated With Low‐Dose Edoxaban: A Post Hoc Analysis of a Randomized Controlled TrialJournal of the American Heart Association · 2026
20. Real-world changes in lipid-lowering therapy use and LDL-C goal attainment in high and very high cardiovascular risk patients in the UK: a secondary analysis of the European SANTORINI study 1-year follow-upBMJ Open · 2026